LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.01
+1.94%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$10.56
From 52W high−71.48%
Volume400924.00
Market cap$269.80M
P/E (TTM)—
P/S (TTM)9992.7x
Div yield—
Key dataSep 18, 2026
Open
$10.56
From 52W high
−71.48%
Volume
400924.00
Market cap
$269.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
27.7
MomentumView details →
1D Return
+1.94%
YTD Return
−65.41%
SummaryUpdated Jun 1, 2026
Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a clinical-stage biotechnology company founded in 2018 and headquartered in South San Francisco, California. The company went public in June 2021 and specializes in developing novel T cell therapies for patients with solid tumors. Lyell focuses on overcoming the limitations of current cancer immunotherapies by reprogramming T cells to maintain their effectiveness against cancer over extended periods, addressing a critical challenge in oncology where T cells often become exhausted and lose their cancer-fighting capabilities.
Similar companies
Latest newsMore news →
Lyell Immunopharma completed the technology transfer of its GCC-targeted CAR T-cell candidate LYL273 to its LyFE Manufacturing Center in Bothell, Washington, following FDA review.10d agoLyell Immunopharma reported its Q2 2026 financial results, with revenue of $4,000, a GAAP net loss of $44.8 million, and cash and marketable securities of $228.0 million as of June 30, 2026.46d ago